The Journal of American Medical Association (JAMA) Publishes Elinzanetant Phase III Data
Elinzanetant, a dual NK-1 and 3 receptor antagonist, showed efficacy and safety in Phase III OASIS 1 and 2 studies for treating moderate to severe VMS in menopause, reducing VMS frequency and severity, and improving sleep disturbances and quality of life.
Related Clinical Trials
Highlighted Terms
Related News
OASIS 3 study supports elinzanetant's efficacy and safety over 52 weeks, with no endometrial hyperplasia or hepatotoxicity observed. Data to be presented at 2024 TMS annual meeting.
Elinzanetant showed positive safety and efficacy in treating moderate-to-severe vasomotor symptoms (VMS) in a phase 3 trial, reducing VMS frequency by -1.6 per day compared to placebo at week 12, with maintained efficacy over 52 weeks. No significant safety issues were reported, supporting previous OASIS trials.
Bayer presents OASIS 3 Phase III study results for elinzanetant, showing significant reduction in moderate to severe vasomotor symptoms (VMS) and sustained safety over 52 weeks, to be discussed at The Menopause Society's 2024 annual meeting. Elinzanetant, a dual neurokinin-1 and -3 receptor antagonist, aims to treat VMS associated with menopause non-hormonally.
Bayer submitted a New Drug Application (NDA) to the U.S. FDA for elinzanetant, an investigational compound for treating moderate to severe vasomotor symptoms (VMS) associated with menopause, based on positive results from Phase III OASIS 1, 2, and 3 studies. Elinzanetant, a non-hormonal option, significantly reduced VMS frequency and severity with a favorable safety profile, marking a milestone in addressing women's health needs globally.
Bayer presents OASIS 3 study results on elinzanetant's efficacy and safety for menopause-related VMS at TMS annual meeting. Elinzanetant, a dual NK-1 and 3 receptor antagonist, shows potential as a non-hormonal treatment. Bayer has submitted a New Drug Application to the FDA and plans to seek marketing authorizations globally.
Bayer presents OASIS 3 study results at TMS 2024, showing elinzanetant's efficacy in reducing moderate to severe vasomotor symptoms (VMS) associated with menopause, with sustained safety over 52 weeks. Elinzanetant, a dual neurokinin-1 and -3 receptor antagonist, met primary and secondary endpoints, maintaining VMS reductions and improving sleep disturbances and quality of life. Bayer plans to seek marketing authorizations globally.
Elinzanetant, a dual NK-1 and 3 receptor antagonist, showed efficacy and safety in Phase III OASIS 1 and 2 studies for treating moderate to severe VMS in menopause, reducing VMS frequency and severity, and improving sleep disturbances and quality of life.
Bayer presents Phase III study OASIS 3 results for elinzanetant at The Menopause Society 2024 annual meeting, showing sustained efficacy and safety over 52 weeks.